GLPBio

Ectoine

Catalog No.: GC39290Purity:>99.00%Synonyms: Ectoin, NSC 614616, Pyrostatin B
Ectoine is a cyclic amino acid derivative produced by bacteria living in extreme environments, which exerts cytoprotective effects through osmoregulation.

Products are for research use only. Not for human use. We do not sell to patients.


Ectoine
Cas No.: 96702-03-3
10mM (in 1mL Water)In Stock
$43.00
1
5gIn Stock
$93.00
1
10gIn Stock
$166.00
1
25gIn Stock
$366.00
1
50gIn Stock
$548.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Ectoine is a cyclic amino acid derivative produced by bacteria living in extreme environments, which exerts cytoprotective effects through osmoregulation[1]. By binding to water molecules, ectoine forms a stable protective hydration shell around cellular components, safeguarding cell structures from damage caused by environmental factors and helping maintain the natural folding state of proteins[2]. Ectoine has been widely used in high-end skincare products, anti-allergic agents, and neuroprotection-related fields due to the compound's favorable safety profile and ability to repair cellular barriers[3,4].

In vitro, pretreatment of human red blood cells with ectoine (0-5%) for 1h protected the cells from damage induced by SDS treatment, with higher concentrations of ectoine providing stronger membrane protection[5]. When co-incubated with 25μM amyloid-β peptide (Aβ42) for 72h, ectoine (25μM-100mM) concentration-dependently reduced Thioflavin T (ThT)-induced fluorescence, indicating fewer cross-β-sheet structures. Notably, 100mM ectoine significantly inhibited Aβ42 fibril aggregation[6]. Pretreatment of human neutrophils with 1mM ectoine for 2h, followed by co-incubation with inflammatory mediators such as 300nM leukotriene B4 (LTB4) and 33μg/mL carbon nanoparticles (CNP) for 16h, significantly restored neutrophil apoptosis rates that were suppressed by these stimuli[7].

In vivo, topical administration of ectoine (0.5-2.0%; 5μL/eye; 4 times daily) in a dry eye model in C57BL/6 mice for 5 days improved corneal smoothness in a concentration-dependent manner. Both 1.0% and 2.0% ectoine restored corneal smoothness to near or complete normality[8]. A single co-administration of ectoine (1mM) with CNP (2.5mg/kg) into the lungs of Fisher 344 rats significantly reduced neutrophil counts and cinc-1 levels from 48 to 168h, demonstrating notable and sustained anti-inflammatory effects[7].

References:
[1] WANG K, CUI B, WANG Y, et al. Microbial production of ectoine: a review[J]. ACS Synthetic Biology, 2025, 14(2): 332-342.
[2] NG H S, WAN P K, KONDO A, et al. Production and recovery of ectoine: A review of current state and future prospects[J]. Processes, 2023, 11(2): 339.
[3] KAUTH M, TRUSOVA O V. Topical ectoine application in children and adults to treat inflammatory diseases associated with an impaired skin barrier: a systematic review[J]. Dermatology and Therapy, 2022, 12(2): 295-313.
[4] BUJAK T, ZAGÓRSKA-DZIOK M, NIZIOŁ-ŁUKASZEWSKA Z. Complexes of ectoine with the anionic surfactants as active ingredients of cleansing cosmetics with reduced irritating potential[J]. Molecules, 2020, 25(6): 1433.
[5] GRAF R, ANZALI S, BUENGER J, et al. The multifunctional role of ectoine as a natural cell protectant[J]. Clinics in Dermatology, 2008, 26(4): 326-333.
[6] KANAPATHIPILLAI M, LENTZEN G, SIERKS M, et al. Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer’s β-amyloid[J]. FEBS Letters, 2005, 579(21): 4775-4780.
[7] SYDLIK U, PEUSCHEL H, PAUNEL-GÖRGÜLÜ A, et al. Recovery of neutrophil apoptosis by ectoine: a new strategy against lung inflammation[J]. European Respiratory Journal, 2013, 41(2): 433-442.
[8] CHEN X, LIN N, LI J M, et al. Ectoine, from a natural bacteria protectant to a new treatment of dry eye disease[J]. Pharmaceutics, 2024, 16(2): 236.

Protocol

Cell experiment [1]:

Cell lines

Human erythrocytes

Preparation Method

Human erythrocytes (2 × 108cells/mL) are treated for 1h with 0%, 0.1%, 0.5%, 1%, and 5% ectoine. Then cells are stressed for 10min with 0% to 0.04% SDS solution, and the number of cells in lysis is determined spectroscopically via the content of free hemoglobin.

Reaction Conditions

0%, 0.1%, 0.5%, 1%, and 5%; 1h

Applications

Etoine protects the cells from damage caused by SDS treatment. The erythrocytes pretreated with ectoine are shown to be more resistant to membrane damage by SDS than those of untreated cells. No stabilizing effect was observed in cells without ectoine, in which maximum erythrocyte damage occurred (0% increase of membrane stability). The higher the ectoine concentration, the greater the protective effect against membrane damage.

Animal experiment [2]:

Animal models

Dry eye model (C57BL/6 mice)

Preparation Method

An experimental dry eye model was induced via desiccating stress (DS) in female C57BL/6 mice (DS mice). The DS mice were treated with topical administration via instillation of 5µL/eye of ectoine in PBS at different concentrations (0.5, 1.0 and 2.0%), 4 times daily during exposure to desiccation for 5 days. On day 5, clinical signs of dry eye and corneal damage were assessed via a stereo microscopy and Oregon Green dextran fluorescein staining.

Dosage form

0.5, 1.0, 2.0%; 5µL/eye; 4 times daily; topical administration via instillation

Applications

Topical administration of 0.5, 1.0, and 2.0% of ectoine in DS mice improved corneal smoothness in a concentration-dependent manner, and ectoine at 1.0 and 2.0% significantly restored the corneal smoothness to near or completely normal condition, with a corneal smoothness score of 1.80 ± 0.92 and 1.20 ± 1.03, respectively.

References:
[1] GRAF R, ANZALI S, BUENGER J, et al. The multifunctional role of ectoine as a natural cell protectant[J]. Clinics in Dermatology, 2008, 26(4): 326-333.
[2] CHEN X, LIN N, LI J M, et al. Ectoine, from a natural bacteria protectant to a new treatment of dry eye disease[J]. Pharmaceutics, 2024, 16(2): 236.

Product Documents

Purity:>99.00%Appearance:A solid

Chemical Properties

CAS No.
96702-03-3
Synonyms
Ectoin, NSC 614616, Pyrostatin B
SMILES
O=C([C@H]1NC(C)=NCC1)O
Molecular Formula
C6H10N2O2
Molecular Weight
142.16
Solubility
Water : 250 mg/mL (1758.58 mM)
Storage
4°C, protect from light
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Ectoine

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%